Perinatal Depression Prevention: A Systematic Evidence Review
Researchers determined that counseling was the intervention associated with the greatest reduction in perinatal depression.
Pregnancy
Prenatal and Infant Pesticide Exposure Associated With Autism Spectrum Disorder
Risk of autism spectrum disorder with and without intellectual disability increases with prenatal and infant exposure to several common ambient pesticides.
Buprenorphine Use Up, Methadone Use Down for Pregnant Women
From 2009 to 2015, the prevalence of methadone use decreased and buprenorphine use increased among Medicaid-enrolled pregnant women with opioid use disorder.
Maternal Mental Disorders Affect Primary School Completion in Offspring
Maternal mental disorders and the timing of their onset are associated with completion of primary education in offspring.
Regional Variance in Prevalence of Opioid Use Disorder Diagnosis, Treatment During Pregnancy
The presence of civil or criminal penalties for OUD diagnosis during pregnancy was associated with the prevalence of OUD diagnosis.
Maternal Infection in Pregnancy Increases Risk for Autism, Depression in Offspring
Maternal infection during pregnancy may be partially responsible for autism and depression in exposed offspring.
No Clinically Relevant ADHD Risk With Prenatal Benzodiazepine, Z-Hypnotic Exposure
Investigators found no substantial increased risk for greater fine motor deficits or ADHD traits in offspring exposed to benzodiazepines or hypnotics at different gestational time points or for a longer duration.
Background, Lifestyle Characteristics Associated With Timing of Perinatal Depression Onset
Researchers analyzed pregnant women in the BASIC cohort to determine whether certain lifestyle and background characteristics are linked to an increased risk of developing depression at a specific stage of the perinatal period.
Increased Prenatal Nicotine Exposure Associated With Higher Risk for ADHD
Higher levels of prenatal nicotine are associated with greater risk for attention-deficit/hyperactivity disorder in children.
Zulresso Approved as First Treatment for Postpartum Depression
The Food and Drug Administration (FDA) has approved Zulresso (brexanolone; Sage Therapeutics) injection for the treatment of postpartum depression in adult women, the first drug to be approved for this indication. Zulresso, an analogue of the endogenous human hormone allopregnanolone, is intended for continuous intravenous (IV) infusion over 2.5 days following a titration schedule. It…
Next post in Depressive Disorder
